The Connecticut Department of Consumer Protection’s (DCP) Drug Control Division has selected the BioTrack software for seed-to-sale tracking of the state’s medical and adult-use cannabis, according to a Westfair report. The inventory system is a product of Consultants Consortium Inc. and its partner Forian.
DCP Commissioner Michelle H. Seagull said the information will allow state regulators “to see what is currently available in both markets, project future inventory, and identify any potential diversion in the markets.”
“Being able to track the state’s cannabis inventory from seed to sale will allow the department to monitor cannabis production and inventory as it moves from the earliest phases of growth to when it reaches the qualifying patient or consumer.” — Seagull to Westfair
Information collected by the BioTrack system will be used by the DCP and the Department of Revenue Services and will be made available to other entities, including law enforcement, as required under the state’s adult-use cannabis law, which was approved by lawmakers and signed by Gov. Ned Lamont (D) in June.
While adult-use sales are expected in Connecticut sometime next year, Seagull warned in September that the state’s timeline for adult-use cannabis sales may take longer than legislators first thought.
“We’ve been suggesting that there will likely be sales by the end of 2022, and we’re still aspiring for that,” she told the Connecticut Examiner. “Obviously, we have to see how things play out in the next few months.”
Seagull said that unknowns, such as who might qualify for a social equity license, could contribute to the delay.
Exclusive offer from our sponsor:
Get daily news insights in your inbox. Subscribe